4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Fujian Haixi Pharmaceuticals Co., Ltd. (2637) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Fuzhou, China with about 200 employees. Its market capitalization is roughly HK$13 billion. In the fiscal year ended 2025-12-31, 2637 reported CNY 582M in revenue and CNY 177M in net income.
Fujian Haixi Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical products in China. The company offers drugs for oncology, ophthalmology, respiratory, digestion, cardiovascular, endocrine, and nervous systems, and inflammation.
Interactive charts & full statements → Open the 2637 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | CNY 582M | — |
| Gross Profit | CNY 486M | — |
| Operating Income (EBIT) | CNY 197M | — |
| Net Income | CNY 177M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | CNY 1.8B | — | — | — |
| Total Liabilities | CNY 253M | — | — | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2637 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms